Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) have earned an average recommendation of “Hold” from the five ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $14.00.
A number of research firms have commented on ATRA. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Canaccord Genuity Group restated a “buy” rating and issued a $13.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, August 13th. Mizuho raised Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and reduced their price objective for the company from $25.00 to $18.00 in a research note on Friday, August 16th. Finally, The Goldman Sachs Group lowered their target price on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating on the stock in a research note on Wednesday, July 17th.
Read Our Latest Research Report on ATRA
Institutional Inflows and Outflows
Atara Biotherapeutics Stock Performance
ATRA opened at $8.60 on Thursday. The stock has a market capitalization of $41.43 million, a P/E ratio of -0.16 and a beta of 0.50. Atara Biotherapeutics has a one year low of $4.96 and a one year high of $39.50. The business’s 50-day simple moving average is $8.05 and its 200-day simple moving average is $10.93.
Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($3.10) EPS for the quarter, missing the consensus estimate of ($1.56) by ($1.54). The business had revenue of $28.64 million during the quarter, compared to the consensus estimate of $48.30 million. On average, equities research analysts forecast that Atara Biotherapeutics will post -12.09 EPS for the current fiscal year.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.
Further Reading
- Five stocks we like better than Atara Biotherapeutics
- EV Stocks and How to Profit from Them
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How is Compound Interest Calculated?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.